1.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
2.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
3.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
4.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
5.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
6.c-Kit signaling confers damage-resistance to sweet taste cells upon nerve injury.
Su Young KI ; Jea Hwa JANG ; Dong-Hoon KIM ; Yong Taek JEONG
International Journal of Oral Science 2025;17(1):57-57
Taste buds relay taste sensory information to the primary taste neurons but depend on those same neurons for essential components to maintain function. While denervation-induced taste bud degeneration and subsequent regeneration were discovered decades ago, the mechanisms underlying these phenomena (e.g., heterogenous cellular responses to nerve injury and the signaling pathways involved) remain poorly understood. Here, using mouse genetics, nerve injury models, pharmacologic manipulation, and taste bud organoid models, we identify a specific subpopulation of taste cells, predominantly c-Kit-expressing sweet cells, that exhibit superior resistance to nerve injury. We found the c-Kit inhibitor imatinib selectively reduced the number of residual c-Kit-expressing sweet cells at post-operation week 2, subsequently attenuating the re-emergence of other type II cells by post-operation week 4. In taste bud organoids, c-Kit-expressing cells were resistant to R-spondin withdrawal but susceptible to imatinib, while other taste cell types showed the opposite behavior. We also observed a distinct population of residual taste cells that acquired stem-like properties, generating clonal descendent cells among suprabasal keratinocytes independent of c-Kit signaling. Together, our findings reveal that c-Kit signaling confers resilience on c-Kit-expressing sweet cells and supports the broader reconstruction of taste buds during the later regenerative stage following nerve injury.
Animals
;
Taste Buds/metabolism*
;
Proto-Oncogene Proteins c-kit/metabolism*
;
Mice
;
Signal Transduction
;
Imatinib Mesylate/pharmacology*
;
Mice, Inbred C57BL
7.Practice guidelines for managing extrahepatic biliary tract cancers
Hyung Sun KIM ; Mee Joo KANG ; Jingu KANG ; Kyubo KIM ; Bohyun KIM ; Seong-Hun KIM ; Soo Jin KIM ; Yong-Il KIM ; Joo Young KIM ; Jin Sil KIM ; Haeryoung KIM ; Hyo Jung KIM ; Ji Hae NAHM ; Won Suk PARK ; Eunkyu PARK ; Joo Kyung PARK ; Jin Myung PARK ; Byeong Jun SONG ; Yong Chan SHIN ; Keun Soo AHN ; Sang Myung WOO ; Jeong Il YU ; Changhoon YOO ; Kyoungbun LEE ; Dong Ho LEE ; Myung Ah LEE ; Seung Eun LEE ; Ik Jae LEE ; Huisong LEE ; Jung Ho IM ; Kee-Taek JANG ; Hye Young JANG ; Sun-Young JUN ; Hong Jae CHON ; Min Kyu JUNG ; Yong Eun CHUNG ; Jae Uk CHONG ; Eunae CHO ; Eui Kyu CHIE ; Sae Byeol CHOI ; Seo-Yeon CHOI ; Seong Ji CHOI ; Joon Young CHOI ; Hye-Jeong CHOI ; Seung-Mo HONG ; Ji Hyung HONG ; Tae Ho HONG ; Shin Hye HWANG ; In Gyu HWANG ; Joon Seong PARK
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(2):161-202
Background:
s/Aims: Reported incidence of extrahepatic bile duct cancer is higher in Asians than in Western populations. Korea, in particular, is one of the countries with the highest incidence rates of extrahepatic bile duct cancer in the world. Although research and innovative therapeutic modalities for extrahepatic bile duct cancer are emerging, clinical guidelines are currently unavailable in Korea. The Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with related societies (Korean Pancreatic and Biliary Surgery Society, Korean Society of Abdominal Radiology, Korean Society of Medical Oncology, Korean Society of Radiation Oncology, Korean Society of Pathologists, and Korean Society of Nuclear Medicine) decided to establish clinical guideline for extrahepatic bile duct cancer in June 2021.
Methods:
Contents of the guidelines were developed through subgroup meetings for each key question and a preliminary draft was finalized through a Clinical Guidelines Committee workshop.
Results:
In November 2021, the finalized draft was presented for public scrutiny during a formal hearing.
Conclusions
The extrahepatic guideline committee believed that this guideline could be helpful in the treatment of patients.
8.Strategies to Improve Smoking Cessation for Participants in Lung Cancer Screening Program: Analysis of Factors Associated with Smoking Cessation in Korean Lung Cancer Screening Project (K-LUCAS)
Yeol KIM ; Jaeho LEE ; Eunju LEE ; Juntae LIM ; Yonghyun KIM ; Choon-Taek LEE ; Seung Hun JANG ; Yu-Jin PAEK ; Won-Chul LEE ; Chan Wha LEE ; Hyae Young KIM ; Jin Mo GOO ; Kui Son CHOI ; Boyoung PARK ; Duk Hyoung LEE ; Hong Gwan SEO
Cancer Research and Treatment 2024;56(1):92-103
Purpose:
Smoking cessation intervention is one of the key components of successful lung cancer screening program. We investigated the effectiveness and related factors of smoking cessation services provided to the participants in a population-based lung cancer screening trial.
Materials and Methods:
The Korean Lung Cancer Screening Project (K-LUCAS) is a nationwide, multi-center lung cancer screening trial that evaluates the feasibility of implementing population-based lung cancer screening. All 5,144 current smokers who participated in the K-LUCAS received a mandatory smoking cessation counseling. Changes in smoking status were followed up using a telephone survey in 6 months after lung cancer screening participation. The lung cancer screening’s impact on smoking cessation is analyzed by variations in the smoking cessation interventions provided in screening units.
Results:
Among 4,136 survey responders, participant’s motivation to quit smoking increased by 9.4% on average after lung cancer screening. After 6 months from the initial screening, 24.3% of participants stopped smoking, and 10.6% of participants had not smoked continuously for at least 6 months after screening. Over 80% of quitters stated that participation in lung cancer screening motivated them to quit smoking. Low-cost public smoking cessation program combined with lung cancer screening increased the abstinence rates. The smokers were three times more likely to quit smoking when the smoking cessation counseling was provided simultaneously with low-dose computed tomography screening results than when provided separately.
Conclusion
A mandatory smoking cessation intervention integrated with screening result counselling by a physician after participation in lung cancer screening could be effective for increasing smoking cessation attempts.
9.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part I. Skin care and topical treatment
Eun LEE ; Hwan Soo KIM ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2024;12(4):170-176
Atopic dermatitis is one of the most common chronic skin inflammatory diseases in children. Appropriate treatment is difficult due to chronic course with frequent exacerbations, especially in children. Treatment requires caution due to a lack of safety data and information regarding the long-term prognosis of management strategies. The Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) published the Atopic Dermatitis Treatment Guidelines in 2008, which has been used to direct atopic dermatitis treatment. Accumulating evidence suggests that the guidelines need to be updated regarding bathing methods (duration of bath, temperature, etc.), wet wrap therapy, and topical treatments in line with environmental changes over time and changes in the management strategies of atopic dermatitis. This KAPARD guidelines for atopic dermatitis applied an adaptation based on a systematic review and analysis of selected literature. They are intended to support front-line doctors treating pediatric and adolescent patients with atopic dermatitis in making reasoned, safe, effective empirical treatment decisions. In Part I of the KAPARD guidelines for atopic dermatitis, we included evidence-based skin care management strategies and topical treatment options.
10.Prognostic Value of Retinoblastoma in Small Intestinal Adenocarcinoma:A Multicenter Retrospective Study
Sun-Young JUN ; Seung-Mo HONG ; Kee-Taek JANG
Journal of Korean Medical Science 2024;39(50):e335-
Background:
The retinoblastoma (RB) protein which is encoded by RB gene selectively provides a cell type-specific function in malignancies. In colorectal carcinoma, RB has been highly expressed and related cyclin/cyclin-dependent kinase 4/6 inhibitors have shown improved therapeutic effects in some patients. However, little is known about RB in small intestinal adenocarcinoma (SIAC).
Methods:
Here, we conducted a multi-institutional study of RB expression in 229 surgically resected SIACs to explore the clinicopathologic and prognostic implications and the relationship with microsatellite instability (MSI) status and KRAS mutations.
Results:
High RB expression (RBHigh ) was more commonly observed in SIACs (76/229, 33%) than in normal small intestinal mucosa (27/188, 14%; P < 0.001). RBHigh was associated with nodular growth patterns (P = 0.028), the absence of lymphovascular (P = 0.001) and perineural invasion (P = 0.048), and a lower T category (P = 0.042) and indicated better overall survival (P = 0.003). In multivariate analysis, RBHigh (P = 0.049) was an independent prognostic predictor of better prognosis, along with younger patient age (P = 0.049), the absence of retroperitoneal seeding (P = 0.004), lower tumor stage (P < 0.001), and MSI (P = 0.005). The prognostic impact of RB expression was consistently observed regardless of MSI status and specifically persistent in SIACs with lower stages (stages I and II).
Conclusion
RBHigh was related to favorable clinicopathologic SIAC characteristics and indicated better patient prognosis. The prognostic predictability of RB was found in SIACs with lower stages, independent of MSI status. RB expression is a reliable and potent prognostic indicator for SIAC and may aid in selecting chemotherapy for patients.

Result Analysis
Print
Save
E-mail